spara0015">We sought to identify A fumigatus sensitization in patients with CF by using the basophil activation test (BAT).
spara0020">Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify A fumigatus sensitization. Serologic (total and A fumigatus–specific IgE), pulmonary function, and body mass index measurements were performed.
spara0025">The BAT discriminates A fumigatus–sensitized from nonsensitized patients with CF. Persistent isolation of A fumigatus in sputum is a significant risk factor for A fumigatus sensitization. Levels of the A fumigatus–stimulated basophil activation marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus–sensitized but not nonsensitized patients with CF. Total and A fumigatus–specific IgE, but not IgG, levels are increased in A fumigatus–sensitized patients with CF and ABPA when compared with those in A fumigatus–sensitized and nonsensitized patients with CF without ABPA. Itraconazole treatment did not affect A fumigatus sensitization.
spara0030">Combining the BAT with routine serologic testing allows classification of patients with CF into 3 groups: nonsensitized, A fumigatus–sensitized, and ABPA. Accurate and prompt identification of A fumigatus–associated clinical status might allow early and targeted therapeutic intervention, potentially improving clinical outcomes.